Sclerotic Metaphyseal Bands Secondary to Denosumab

Bowen, Mindy; Botchu, Rajesh; James, Steven; Davies, A. M.

doi:10.21569/2222-7415-2019-9-3-235-237

Rejr

2019

DOI: 10.21569/2222-7415-2019-9-3-235-237

|View full text |Cite

Sclerotic Metaphyseal Bands Secondary to Denosumab

Mindy Bowen¹,

Rajesh Botchu²,

Steven James³

et al.

Abstract: here is a long list of differential diagnoses for sclerotic metaphyseal bands identified on radiographs. We present a case of generalised sclerotic metaphyseal bands that occurred following the administration of denosumab, a human monoclonal antibody, used to treat an aggressive aneurysmal bone cyst (ABC).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Exploring Denosumab’s potential in aneurysmal bone cyst treatment: A scoping review

Sandhu,

Ajit Singh,

Puri

2024

J Orthop Surg (Hong Kong)

View full text Add to dashboard Cite

Background: Denosumab effectively treats RANKL-mediated bone disorders by inhibiting osteoclast activity. While approved for giant cell tumours, its role in aneurysmal bone cysts (ABC) remains unclear. This review explores denosumab’s application in ABCs, focusing on its role, outcomes, and adverse effects. Methods: A scoping review adhering to PRISMA Extension for Scoping Reviews guidelines was conducted. The search involved five databases from inception until 31 December 2023. Results: From an initial 390 studies, 29 were selected post-screening involving 67 patients. The most common ABC sites were the spine ( n = 42) and pelvis ( n = 7). Denosumab served as primary treatment in 25 patients (37.3%), neoadjuvant in 11 (16.4%), second-line therapies after inadequate initial therapies in 24 (35.8%), and adjunct therapy in seven cases. All patients demonstrated favourable clinical and radiological responses post-denosumab. 10 patients (15%) experienced tumour recurrences: six after denosumab discontinuation (3-17 months post-cessation), three post-surgery following neoadjuvant denosumab, and one during ongoing treatment. Adverse effects reported were hypocalcaemia ( n = 10), hypercalcemia ( n = 14), and sclerotic metaphyseal bands ( n = 2), all in the paediatric age group. While hypocalcaemia surfaced early in denosumab therapy, hypercalcaemia manifested 2.5-6 months post-discontinuation, mainly managed with bisphosphonates. Fewer than half of the studies had follow-ups that exceeded 2 years. Conclusion: Denosumab may be an effective therapy for ABC, especially for high-risk cases like spinal and pelvic tumours. It can also be utilized as a second-line for recurrence/failed initial intervention or as neoadjuvant therapy. Concerns exist about tumour recurrence and rebound hypercalcemia, necessitating careful monitoring, longer follow-up, and prophylactic measures. Prospective clinical trials are warranted for deeper insights.

show abstract

Exploring Denosumab’s potential in aneurysmal bone cyst treatment: A scoping review

Sandhu,

Ajit Singh,

Puri

2024

J Orthop Surg (Hong Kong)

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Sclerotic Metaphyseal Bands Secondary to Denosumab

Cited by 1 publication

References 6 publications

Exploring Denosumab’s potential in aneurysmal bone cyst treatment: A scoping review

Exploring Denosumab’s potential in aneurysmal bone cyst treatment: A scoping review

Contact Info

Product

Resources

About